International Track 200

In the past five years, Slough-based Chiltern has conducted almost 2,000 clinical trials in 47 countries for clients in the pharmaceutical and biotech sectors. Chief executive Jim Esinhart, 54, saw international turnover reach £331.3m last year, partly due to acquisitions, including that of US clinical research company Theorem in 2015.

This profile reflects the company at time of publication and does not reflect any changes that may have subsequently occurred. Fast Track and its sponsors do not endorse, guarantee or recommend investment in any of the companies.

Company details
CompanyChiltern International Group
ActivityContract research provider
2-yr av intl sales growth pa65.32%
International sales £000s*331,300
Total sales £000s*400,178

If applicable:

* Supplied by company † Annualised figure